Table 1. Correlation between FGF4 and clinicopathologic characteristics of lung adenocarcinoma.
| Variable | Total(%) | FGF4 expression | χ2 | P value | ||
|---|---|---|---|---|---|---|
| − | + | ++ | ||||
| Age | ||||||
| <50 | 7 (11.7) | 4 (57.1) | 1(14.3) | 2(28.6) | 3.021 | 0.221 |
| ≥50 | 53 (88.3) | 18 (34] | 26(49.1) | 9 (17) | ||
| Sex | ||||||
| Male | 26 (43.3) | 10 (38.5) | 9 (34.6) | 7(26.9) | 2.986 | 0.225 |
| Female | 34 (56.7) | 12 (35.3) | 18 (52.9) | 4(11.8) | ||
| Lobe of primary tumor | ||||||
| Upper | 37(61.7) | 14(37.8) | 16(43.2) | 7(18.9) | 0.120 | 0.942 |
| Middle/Lower | 23(38.3) | 8(34.8) | 11(47.8) | 4(17.4) | ||
| Tumor size(cm) | ||||||
| ≥3 | 28 (46.7) | 9 (31.2) | 14 (50) | 5(17.9) | 0.591 | 0.744 |
| <3 | 32 (53.3) | 13 (40.6) | 13(40.6) | 6(18.8) | ||
| Histological type | ||||||
| Lepidic predominant | 21 (35.0) | 12 (57.1) | 7 (33.3) | 2(9.5) | 15.952 | 0.043* |
| Acinar predominant | 17 (28.3) | 4(23.5) | 12(70.6) | 1(5.9) | ||
| Solid predominant | 10 (16.6) | 3(30.0) | 4(40.0) | 3(30.0) | ||
| Micropapillary predominant | 8(13.3) | 1(12.5) | 3(37.5) | 4(50.0) | ||
| Papillary predominant | 4(6.7) | 2(50.0) | 1(25.0) | 1(25.0) | ||
| TNM stage | ||||||
| TNM I | 33(55.0) | 18(54.5) | 11(33.3) | 4(12.1) | 17.197 | 0.009* |
| TNM II | 14(23.3) | 2(14.3) | 10(71.4) | 2(14.3) | ||
| TNM III | 7(11.7) | 1(14.3) | 2(28.6) | 4(57.1) | ||
| TNM IV | 6(10.0) | 1(16.7) | 4(66.7) | 1(16.7) | ||
| Metastasis | ||||||
| Present | 23(38.3) | 4 (17.4) | 13(56.5) | 6(26.1) | 6.103 | 0.047* |
| Absent | 37(61.7) | 18 (48.6) | 14(37.8) | 5(13.5) | ||
*
Significantly different.